A 58-year-old man with a 40 pack-year smoking history and chronic cough presents with hemoptysis for 2 weeks. Chest X-ray shows a 3 cm irregular opacity in the left upper lobe with ill-defined margins. There are no mediastinal lymph nodes or pleural effusion on CXR. The patient is referred for further evaluation to assess resectability and staging. Which single imaging modality should be performed next?

Explanation

## Clinical Context This patient has a suspicious lung lesion (irregular, ill-defined margins) in a high-risk smoker with hemoptysis—highly suggestive of **primary lung cancer**. The question asks for the imaging modality to assess **resectability and staging**, which requires both local tumor extent and distant metastatic assessment. ## Why PET-CT is the Gold Standard for Lung Cancer Staging **High-Yield:** PET-CT (18F-FDG PET combined with CT chest/abdomen/pelvis) is the investigation of choice for suspected lung cancer because it: - **Confirms malignancy**: 18F-FDG uptake indicates high metabolic activity (sensitivity ~90% for lung cancer) - **Stages the tumor**: Detects mediastinal lymph node involvement (N-staging) and distant metastases (M-staging) in a single study - **Guides treatment**: Identifies patients suitable for surgery (no distant metastases, resectable primary) vs. chemotherapy/radiation - **Detects occult metastases**: Identifies bone, brain, liver, and adrenal metastases missed on CT alone **Key Point:** PET-CT is **mandatory** before any surgical intervention in lung cancer because it upstages 10–15% of patients who appear resectable on CT alone. **Mnemonic: PET-CT in Lung Cancer — "STAGE IT"** - **S**taging (TNM) - **T**umor metabolic activity (confirms malignancy) - **A**drenal/distant metastases - **G**anglia (mediastinal lymph nodes) - **E**xtent of disease - **I**nvestigation before intervention - **T**reatment planning ## Imaging Algorithm for Suspicious Lung Lesion ```mermaid flowchart TD A[Suspicious lung lesion on CXR]:::outcome --> B[Contrast CT chest/abdomen/pelvis]:::action B --> C{Lesion confirmed?<br/>Size >1 cm?}:::decision C -->|Yes, likely malignant| D[PET-CT for staging<br/>and metastatic workup]:::action C -->|No, <1 cm| E[Follow-up CT in 3-6 months]:::action D --> F{Resectable?<br/>No distant mets?}:::decision F -->|Yes| G[Surgical planning<br/>+ staging bronchoscopy if needed]:::action F -->|No| H[Chemotherapy ±<br/>radiation therapy]:::action ``` ## Comparison of Imaging Modalities for Lung Cancer | Modality | Detects Primary Tumor | Lymph Node Staging | Distant Metastases | Metabolic Activity | Gold Standard | |---|---|---|---|---|---| | CXR | Yes (>2 cm) | No | No | No | Screening only | | Contrast CT | Yes | Moderate (size-based) | Moderate (only visible lesions) | No | Initial staging | | **PET-CT** | **Yes** | **High (metabolic)** | **High (whole-body)** | **Yes** | **Yes** | | MRI chest | Yes | Moderate | No | No | Cardiac involvement only | | Bronchoscopy | Yes (central lesions) | Yes (if accessible) | No | No | Diagnosis, not staging | **Clinical Pearl:** While contrast CT is often performed first to characterize the lesion, **PET-CT is essential before treatment planning** because it can change management in 15–20% of patients by identifying occult metastases or ruling out resectability. **Tip:** PET-CT should be performed **after** contrast CT (which provides anatomic detail) but **before** bronchoscopy or surgery. Bronchoscopy is for tissue diagnosis if imaging is inconclusive, not for staging.